Optum Perks coupons cannot be used with insurance copays ... (An active ingredient is what makes a drug work.) Another drug, Zepbound, also contains the same active ingredient and is approved ...

Not long after reporting phase 2 data for one of its obesity candidates that appeared to put it on par with Eli Lilly’s Zepbound, Kailera Therapeutics is preparing for an eventual market launch ...

Eli Lilly is experiencing explosive growth thanks to its diabetes and obesity treatments. Beyond weight loss, the company is quietly building a fast-growing oncology business. This is an enormous ...

While Novo Nordisk's Ozempic is the most mainstream GLP-1 medication, Eli Lilly (NYSE: LLY) has two blockbuster weight loss drugs of its own: Mounjaro and Zepbound. Mounjaro and Zepbound are by ...

Novo is under pressure to boost its development credentials in its rivalry with Zepbound-maker Eli Lilly after a late-stage trial read-out on another next-generation obesity drug known as ...

Eli Lilly (NYSE: LLY) has become a beast in healthcare. The excitement surrounding its GLP-1 drugs, Mounjaro and Zepbound, has helped boost its market capitalization to around $650 billion.

Telehealth company Ro will offer single-dose vials of Eli Lilly's obesity therapy Zepbound in an expansion of the ways patients with a prescription can access the drug. The agreement means Ro has ...

2. Eli Lilly's weight-loss wonders. The Mounjaro and Zepbound producer hopes to close the gap with competitor Novo Nordisk's Ozempic — and take things a step further. Eli Lilly's head of obesity ...

This hormone slows the rate of how the stomach is emptied and regulates blood sugar. Amycretin also works slightly differently than Eli Lilly’s Zepbound and Viking Therapeutics’ experimental VK-2735, ...

and Zepbound, for obesity. If you ask him what he's most excited about, it's not a daily, weekly, or even monthly medicine for weight loss or diabetes control. His eye is trained on a one-and-done ...

Of those, over 215,000 had been prescribed a glucagon-like peptide-1 (GLP-1) agonist receptor — the class of drugs that includes Ozempic, Wegovy, Mounjaro, Zepbound, and others — and 1.7 ...